IASLC

Lung Cancer Considered

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informat...

Vizitează neapărat site-ul podcastului și susține-i creatorul: www.iaslc.org

Autor

IASLC

Categorie

Science

Site-ul podcastului

www.iaslc.org

Cel mai nou episod

17 nov. 2026

Unde asculți?

Podcasturi în aplicație Replaio Radio În curând

Podcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor

Descarcă din Google Play Instalează gratuit Android 10 mil.+ descărcări · nota 4,7+ iOS în curând

Episoade

LCC in Romanian: Management of Unresectable, EGFR-mutated Stage III Lung Cancer in Romania 02.08.2025

LCC in Romanian: Management of Unresectable, EGFR-mutated Stage III Lung Cancer in Romania by IASLC

IASLC - Stigma 29.07.2025

IASLC - Stigma by IASLC

LCC in Japanese: ASCO 2025 Highlights 25.07.2025

LCC in Japanese: ASCO 2025 Highlights by IASLC

Preview: IASLC | ASCO 2025 North American Conference on Lung Cancer 23.07.2025

On December 5, 2025, we will kick off the IASLC ASCO 2025 North America Conference on Lung Cancer. Guest include Dr. Ramesh Rengan, the Peter Wootton Professor and Chair of Radiation Oncology at the University of Washington and Senior Vice President of the Fred Hutchinson Cancer Center and Dr. Kristen Marrone, Associate Professor of Oncology and Director of the Medical Oncology and Hematology Fell...

FDA Approval: Datopotamab Deruxtecan for EGFR NSCLC 18.07.2025

FDA Approval: Datopotamab Deruxtecan for EGFR NSCLC by IASLC

FDA Approval: Sunvozertinib for EGFR Exon 20 15.07.2025

FDA Approval: Sunvozertinib for EGFR Exon 20 by IASLC

LCC in Portuguese: Virtual Tumor Board - EGFR NSCLC 11.07.2025

LCC in Portuguese: Virtual Tumor Board - EGFR NSCLC by IASLC

IASLC_WCLC 2025 Preview 08.07.2025

IASLC_WCLC 2025 Preview by IASLC

Virtual Tumor Board: Resectable EGFR NSCLC 01.07.2025

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Chunxia Su and Dr. Collin Blakely. The case explores resectable EGFR NSCLC.

FDA Approval: Taletrectinib and ROS1 NSCLC 24.06.2025

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enriqueta Felip and Dr. Jorge Nieva join the conversation to help review the data and offer help place this new agent in the proper perspective.

IASLC - ASCO 2025 Highlights 06.06.2025

ASCO 2025 Highlights Guests: Charu Aggarwal, MD, MPH Leslye M. Heisler Professor of Medicine Section Chief, Thoracic and Head & Neck Cancer Associate Director, Penn Center for Cancer Care Innovation (PC3I) University of Pennsylvania Patrick Forde, MBBCh Associate Professor Johns Hopkins University

FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC 27.05.2025

In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new agent, I am joined by two expert thoracic oncologists. I want to welcome Dr. Mor Moskovitz, Head of the Thoracic Medical Oncology Service at Davidoff Cancer Center at the Rabin Medical Center in Petah...

LCC in Korean: Lung Cancer Updates & Future Directions 23.05.2025

LCC in Korean: Lung Cancer Updates & Future Directions by IASLC

Global Advances and Persistent Disparities in Lung Cancer Treatment 20.05.2025

Global Advances and Persistent Disparities in Lung Cancer Treatment by IASLC

Dr. Bryant Lin Teaching My Cancer 06.05.2025

Dr. Bryant Lin Teaching My Cancer by IASLC

AACR 2025 Highlights 02.05.2025

AACR 2025 Highlights by IASLC

What You Should Know About RET-Positive NSCLC: Live from TexasLung25 29.04.2025

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Mihaela Aldea about the key information about RET-positive NSCLC, from diagnostic challenges to treatment selection. Join us in this lively discussion.

Excuse me, What? Top Recommendations for Effective Patient Communication: Live from TexasLung25 22.04.2025

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Eric Singhi and Dr. Misty Shields about patient education and communication. Tune in to hear the top things to discuss during your first oncology visit, including conflict and miscommunication resolution.

ELCC 2025 Highlights: Insights and Review of the Data 05.04.2025

Guest: Dr. Corey Langer is the Director of Thoracic Oncology and Professor of Medicine at the Hospital of the University of Pennsylvania

The Microbiome and Immunotherapy for Lung Cancer 16.03.2025

The Microbiome and Immunotherapy for Lung Cancer by IASLC

LCC in Italian: Virtual Tumor Board - Resectable NSCLC 16.03.2025

LCC in Italian: Virtual Tumor Board - Resectable NSCLC by IASLC

LCC in Mandarin: Virtual Tumor Board - EGFR NSCLC 16.03.2025

LCC in Mandarin: Virtual Tumor Board - EGFR NSCLC by IASLC

Virtual Tumor Board: Targeting Residual Disease 16.03.2025

Virtual Tumor Board: Targeting Residual Disease by IASLC

LCC in Korean: 2024 Lung Cancer Updates 16.03.2025

LCC in Korean: 2024 Lung Cancer Updates by IASLC

Live from TTLC25: Lung Cancer and Brain Metastasis 15.03.2025

Live from TTLC25: Lung Cancer and Brain Metastasis by IASLC

Ascultă podcastul Lung Cancer Considered în Replaio

Radio și podcasturi într-o singură aplicație - gratuit și fără înregistrare. Instaleaz-o azi și nu rata lansarea

Descarcă din Google Play

Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice